Proteinum valosinum continens

Proteinum valosinum continens VCP
Alia nomina	VCP, ALS14, HEL-220, HEL-S-70, IBMPFD, IBMPFD1, TERA, p97, CMT2Y, CDC48
Locus geni (homo)

Chromosoma	9 (humanum)
Locus	9p13.3 (homo)

Fontes externae	OMIM: 601023

Proteinum valosinum continens, abbreviatur VCP, sive Transitionalis ATPasis reticuli endoplasmatici vel p97 (solum mammaliarum ita dictum), est proteinum et membrum familiae proteinorum ATPasis cum munera cellularia varia sociatae (AAA+ quoque dictum)^[1]. Nomen geni est VCP.

Invenitur VCP in eukaryotis et archaeis.

Functio sua principalis est, ut parviora proteina de structuris cellularibus maioribus segregentur.

Natura proteini valosinum continentis recensere

Genus superfamiliae AAA+ recensere

Superfamilia AAA+ attribuitur ATPasis^[2].

Munera proteini p97 recensere

Homeostasis proteinorum recensere

Proteino valosinum continente munera in aliorum proteinorum degradatione iuxta reticulum endoplasmaticum^[3].

Contextus cum morbis neurodegenerativis recensere

Degeneratio lobularis frontotemporalis recensere

Conferatur pagina principalis Degeneratio lobularis frontotemporalis.

Mutationes geni VCP cum degeneratione lobulari frontotemporali sociatae videntur.

Morbus Parkinson recensere

Conferatur pagina principalis Morbus Parkinson.

Contextus cum morbo Parkinson incerti sunt. Alii morbum Parkinson non cum proteino p97 coniunctum putant^[4], alii p97 signum stadii praeclinici morbi Parkinson indicere descripserunt^[5].

Notae recensere

↑ Weihl C. C., Dalal S., Pestronk A., Hanson P. I. (2009). "Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation". Human molecular genetics 15 (2): 189-99
↑ Ogura T., Wilkinson A. J. (Iul 2001). "AAA+ superfamily ATPases: common structure--diverse function". Genes to cells 6 (7): 575-97
↑ Lan B., Chai S., Wang P., Wang K. (2017). "VCP/p97/Cdc48, A Linking of Protein Homeostasis and Cancer Therapy". Current molecular medicine 17 (9): 608-18
↑ Majounie E., Traynor B. J., Chiò A., Restagno G., Mandrioli J., Benatar M., Taylor J. P., Singleton A. B. (Ian 2012). "Mutational analysis of the VCP gene in Parkinson's disease". Neurobiology of aging 33 (1): 209.e1-2
↑ Alieva A., Rudenok M., Filatova E., Karabanov A., Doronina O., Doronina K., Kolacheva A., Ugrumov M., Illarioshkin S., Slominsky P., Shadrina M. (Ian 2017). "VCP expression decrease as a biomarker of preclinical and early clinical stages of Parkinson's disease". Scientific reports 10 (1): 827

Nexus interni

Haec stipula ad biologiam spectat. Amplifica, si potes!

[1] Weihl C. C., Dalal S., Pestronk A., Hanson P. I. (2009). "Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation". Human molecular genetics 15 (2): 189-99

[2] Ogura T., Wilkinson A. J. (Iul 2001). "AAA+ superfamily ATPases: common structure--diverse function". Genes to cells 6 (7): 575-97

[3] Lan B., Chai S., Wang P., Wang K. (2017). "VCP/p97/Cdc48, A Linking of Protein Homeostasis and Cancer Therapy". Current molecular medicine 17 (9): 608-18

[4] Majounie E., Traynor B. J., Chiò A., Restagno G., Mandrioli J., Benatar M., Taylor J. P., Singleton A. B. (Ian 2012). "Mutational analysis of the VCP gene in Parkinson's disease". Neurobiology of aging 33 (1): 209.e1-2

[5] Alieva A., Rudenok M., Filatova E., Karabanov A., Doronina O., Doronina K., Kolacheva A., Ugrumov M., Illarioshkin S., Slominsky P., Shadrina M. (Ian 2017). "VCP expression decrease as a biomarker of preclinical and early clinical stages of Parkinson's disease". Scientific reports 10 (1): 827

[1]

[2]

[3]

[4]

[5]